Elicio Therapeutics (ELTX) investor relations material

Investment highlights and platform overview

• Developing novel lymph node-targeted, off-the-shelf cancer immunotherapies using the AMP platform, designed to generate robust immune responses by targeting lymph nodes, the central hub of immune activation.

• Proof-of-concept demonstrated in two completed Phase 1 trials and a randomized Phase 2 trial, with ELI-002 targeting mKRAS mutations present in 25% of solid tumors.

• Randomized Phase 2 monotherapy in pancreatic cancer showed a hazard ratio of 0.65 and p=0.0484 in the RO subgroup, with multiple complete responses observed in recurrent metastatic PDAC patients after subsequent checkpoint inhibitor therapy.

• Value-creating catalysts include initiation of a Phase 1 trial in metastatic PDAC and preparation for a Phase 3 adjuvant PDAC trial.

Clinical pipeline and strategy

• Pipeline includes ELI-002 7P for mKRAS PDAC in adjuvant, metastatic, and neoadjuvant settings, with expansion opportunities for other mutations (mBRAF, mTP53) and solid tumors.

• Near-term focus is on Phase 1 initiation in metastatic PDAC and Phase 3 preparation in adjuvant PDAC, with investigator-initiated trials in neoadjuvant settings.

• Staged development pathway for ELI-002 7P + RAS inhibitor +/- checkpoint inhibitor in metastatic PDAC, with rapid readouts and capital-efficient small cohorts.

Clinical results and differentiation

• ELI-002 7P demonstrated multiple confirmed complete responses in metastatic PDAC patients, a rare outcome in this setting, especially in MSS/MMR-proficient disease.

• Complete responses were observed after ELI-002 7P treatment followed by nivolumab-based therapy, with durable responses and biomarker normalization.

• mKRAS-specific T cell responses persisted through subsequent chemotherapy and checkpoint inhibition, with evidence of antigen spreading and polyfunctional T cell activity.

• Early disease-free survival (DFS) separation observed in adjuvant Phase 2 trial, with stronger treatment effect in RO resected patients (HR=0.65, p=0.0484).

• Greater mKRAS-specific T cell responses were strongly associated with improved DFS.